山东痛风中医治疗效果山东治疗痛风去哪好,济南痛风发作可以不处理吗,济南痛风都有什么症状,山东什么可以缓解痛风,山东脚背疼是不是痛风,山东大脚趾突然红肿疼痛,山东痛风怎么办能

OTTAWA, Oct. 3 (Xinhua) -- Many friends and colleagues of Canadian scientist Ralph Steinman reacted with shock when they learned on Monday that Steinman won the Nobel Prize for Medicine and Physiology three days after he died.Since 1974, Nobel Prizes are no longer awarded posthumously, but the Nobel Prize committee said that it had made its choice before Steinman's death.Many of Steinman's friends and colleagues said that they learned of Steinman's death at the same time that they learned of his Nobel Prize, which was awarded for a discovery Steinman made in 1973.Steinman, 68, discovered dendritic cells, which help regulate adaptive immunity, which purges invading microorganisms from the body. Dendritic cells activate T cells, which "remember" the DNA sequence of invading organisms and protect the body from later infections from the same disease."Their work has opened up new avenues for the development of prevention and therapy against infections, cancer and inflammatory disease," the citation said.Monday, the Nobel Committee defended its decision to award the prize to Steinman. "The decision to award the Nobel Prize to Ralph Steinman was made in good faith, based on the assumption that the Nobel Laureate was alive," the foundation said in a statement."The Nobel Foundation thus believes that what has occurred is more reminiscent of the example in the statutes concerning a person who has been named as a Nobel Laureate and has died before the actual Nobel Prize Award Ceremony."It is still unclear who will pick up Steinman's prize at the award ceremony later this year.Steinman, a cell biologist at Rockefeller University in New York City, died of pancreatic cancer on Friday. For more than four years, he had used his own immune therapy discoveries to extend his life."The news is bittersweet, as we also learned this morning from Ralph's family that he passed a few days ago," Rockefeller University President Marc Tessier-Lavigne said in a statement."We are all so touched that our father's many years of hard work are being recognized with a Nobel Prize," Steinman's daughter, Alexis, said in the statement. "He devoted his life to his work and his family, and he would be truly honored."Steinman's heirs will share the 1.5-million U.S. dollar prize with American genetics professor Bruce Beutler and French scientist Jules Hoffmann.Dr. Beutler is professor of genetics and immunology at The Scripps Research Institute in La Jolla, California. Dr. Hoffmann headed a research laboratory in Strasbourg, France, between 1974 and 2009 and served as president of the French National Academy of Sciences between 2007 and 2008."Ralph worked right up until last week," said Michel Nussenzweig, a collaborator of Steinman's at Rockefeller University. "His dream was to use his discovery to cure cancer and infectious diseases like HIV and tuberculosis. It's a dream that's pretty close."Steinman was born in 1943 in Montreal, Canada's second largest city, and studied chemistry and biology at McGill University in his hometown before receiving an MD from Harvard Medical School in Boston in 1968. He joined Rockefeller University in 1970 as a postdoctoral fellow."He was diagnosed with pancreatic cancer four years ago, and his life was extended using a dendritic-cell based immunotherapy of his own design," the university said in a statement.In a statement, Canadian Prime Minister Stephen Harper lauded the three winners of the Nobel for medicine and called the award " a fitting final tribute" to Steinman's life's work."Dr. Steinman shall be honored for all time with this achievement," Harper said. "Canadians will mourn his loss."

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.

BEIJING, Nov. 17 (Xinhua) -- Chinese State Councilor Liu Yandong on Thursday met with a U.S. artist delegation, vowing to promote bilateral cultural and art exchanges.Headed by President and Chief Executive Officer of the Asia Society Vishakha Desai, the delegation will participate in the China-U.S. Forum on the Arts and Culture from Nov. 16-19 in Beijing.Liu welcomed the U.S. artists, noting cultural and art exchanges are an important component of bilateral people-to-people exchanges.She said the founding of the forum established an institutionalized and constructive platform for deepening bilateral relations and friendship between the two peoples.Artists from the two countries should exert their influence and actively promote bilateral cultural exchanges, she said.The forum is organized by the Chinese People's Association for Friendship with Foreign Countries, the Asia Society and the Aspen Institute.An extraordinary line-up of American cultural icons will attend the event, including actress Meryl Streep, film director Joel Coen, musician Yo-Yo Ma, and best-selling author Amy Tan.

RIO DE JANEIRO, Oct. 11 (Xinhua) -- The World Health Organization (WHO) on Tuesday highlighted Brazil's efforts to stop tuberculosis (TB) in its territory.According to a report released by the organization, Brazil achieved significant and sustained improvement in the fight against TB in the past years.Along with Cambodia, China, Uganda, and Tanzania, Brazil is one of the five nations which succeeded in reducing TB death rate in 2010 by half compared with 1990.The number of TB cases in the world fell for the first time in 2010, said the WHO. But with 8.8 million cases, the disease remained a major global health problem, said the organization.Although the TB death rate had significantly dropped over the years, the disease killed 1.4 million people around the world in 2010 alone.